Notable Reporting: What’s Trevena Inc Downside After Touching 52 Week Low?

Notable Reporting: What's Trevena Inc Downside After Touching 52 Week Low?

The stock of Trevena Inc (NASDAQ:TRVN) hit a new 52-week low and has $3.95 target or 11.00% below today’s $4.44 share price. The 9 months bearish chart indicates high risk for the $226.92M company. The 1-year low was reported on Nov, 2 by If the $3.95 price target is reached, the company will be worth $24.96 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 7.11% or $0.34 during the last trading session, hitting $4.44. About 374,347 shares traded hands or 48.03% up from the average. Trevena Inc (NASDAQ:TRVN) has declined 42.20% since March 31, 2016 and is downtrending. It has underperformed by 44.72% the S&P500.

Analysts await Trevena Inc (NASDAQ:TRVN) to report earnings on November, 8. They expect $-0.37 EPS, down 54.17% or $0.13 from last year’s $-0.24 per share. After $-0.37 actual EPS reported by Trevena Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Trevena Inc (NASDAQ:TRVN) Ratings Coverage

Out of 7 analysts covering Trevena Inc (NASDAQ:TRVN), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Trevena Inc has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. As per Tuesday, March 29, the company rating was initiated by FBR Capital. The rating was maintained by JMP Securities on Wednesday, September 2 with “Buy”. The rating was initiated by WallachBeth Capital with “Buy” on Wednesday, March 2. Barclays Capital upgraded Trevena Inc (NASDAQ:TRVN) on Tuesday, September 1 to “Equal-Weight” rating. The firm has “Buy” rating given on Monday, August 3 by Brean Capital. On Tuesday, August 11 the stock rating was maintained by Needham with “Buy”. The company was maintained on Tuesday, September 1 by Cowen & Co.

According to Zacks Investment Research, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.”

More notable recent Trevena Inc (NASDAQ:TRVN) news were published by: which released: “Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine …” on February 22, 2016, also with their article: “Trevena, Inc. Announces Proposed Underwritten Offering of Common Stock” published on September 10, 2015, published: “Trevena, Inc. Announces Pricing of Underwritten Offering of Common Stock” on September 11, 2015. More interesting news about Trevena Inc (NASDAQ:TRVN) were released by: and their article: “Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program …” published on January 19, 2016 as well as‘s news article titled: “Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 …” with publication date: June 08, 2016.

TRVN Company Profile

Trevena Inc., incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. In addition to these three product candidates, it has identified and has completed the Phase I program for TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment